drugset / Trial / NCT00201409

A Randomized Trial of GM-CSF in Patients With ALI/ARDS

NCT00201409 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test the hypothesis that administration of granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) will improve the clinical course and outcome by shortening the duration of mechanical ventilation for these patients.

Timeline

Start
2004-07
Primary completion
2009-05
Completion
2009-06

Outcome

Missed primary endpoint

paper There was no difference in ventilator-free days between groups (10.7 ± 10.3 days placebo vs. 10.8 ± 10.5 days granulocyte-macrophage colony stimulating factor, p = .82). PMID 21926600 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject GM-CSF Protein / enzyme biologic 250 ug/m2 Intravenous